Acadia Pharmaceuticals Inc. · NASDAQ:ACAD
Acadia Pharmaceuticals — Q4 2020 Earnings Presentation
26 slides from Acadia Pharmaceuticals's earnings presentation, Feb 24, 2021
Slide 1: Fourth Quarter and Full Year 2020 Earnings Call
Fourth Quarter and Full Year 2020 Earnings Call February 24, 2021
Slide 2: 4Q and FY20 Earnings Call Agenda
4Q and FY20 Earnings Call Agenda Introduction Mark Johnson | Vice President, Investor Relations CEO Opening Remarks Steve Davis | Chief Executive Officer Financial Update Elena Ridloff | Chief Financial Officer Amanda Morgan | Chief Revenue and Customer Officer Commercial Update Charmaine Lykins | G
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future r
Slide 4: CEO Opening Remarks
CEO Opening Remarks Steve Davis Chief Executive Officer
Slide 5: 2020 Full-Year Highlights
2020 Full-Year Highlights $441.8M FY20 Net Sales ✓ 30% YoY growth for NUPLAZID® in PDP Net Sales (in millions) ✓ Submitted sNDA for pimavanserin for the treatment of $500 hallucinations and delusions associated with DRP ✓ Progressed enrollment in Phase 3 trofinetide program for $400 Rett syndrome (L
Slide 6: Three Strategic Pillars Building a Leading CNS Company
Three Strategic Pillars Drive Deliver Develop Growth of On the DRP Next Wave of NUPLAZID® Opportunity Breakthroughs Building a Leading CNS Company NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease psy
Slide 7: Combined Market Opportunity
Long-Term Growth Strategy Develop Next Wave of Combined Market Opportunity Breakthroughs: Deliver on the • Progressing Development DRP Opportunity: Candidates in 5 Indications • BD Strategy to Grow Pipeline Potential Future 10X Market Opportunity vs. PDP and Leverage CNS Expertise • Targeted Researc
Slide 8: Finance Update
Finance Update Elena Ridloff Chief Financial Officer
Slide 9: 4Q20 Financial Highlights
4Q20 Financial Highlights 4Q20 4Q19 YoY Change (GAAP) (GAAP) Total Revenue $121.0 $98.3 +23% Cost of Product Sales, License Fees and Royalties $5.3 $5.3 0% R&D $62.1 $57.5 +8% SG&A $120.8 $91.9 +31% Net Loss $66.8 $53.0 +26% EPS ($0.42) ($0.34) -24% Provided February 24, 2021 as part of an oral pres
Slide 10: FY2020 Financial Highlights
FY2020 Financial Highlights 2020 2019 YoY Change (GAAP) (GAAP) Total Revenue $441.8 $339.1 +30% Cost of Product Sales, License Fees and Royalties $20.5 $19.6 +5% R&D $319.1 $240.4 +33% SG&A $388.7 $325.6 +19% Net Loss $281.6 $235.3 +20% EPS ($1.79) ($1.60) -12% Cash Balance 12/31/20201 $632.0 1Cash
Slide 11: FY2021 Financial Guidance
FY2021 Financial Guidance FY2021 Guidance Commentary • PDP growth at midpoint of the range reflects ~20% YoY growth NUPLAZID® Net Sales in PDP $510 to $550M • Not including revenue expectations for potential DRP launch in 2021 guidance • Progressing candidates in 5 indications GAAP R&D Expense $300
Slide 12: Commercial Update
Commercial Update Amanda Morgan Chief Revenue and Customer Officer Charmaine Lykins Global Product Planning and Chief Marketing Officer
Slide 13: NUPLAZID Growth in 2020
NUPLAZID® Growth in 2020 2020 Highlights ✓ $441.8M net sales; 30% YoY Growth ✓ Strong continued growth in prescribers despite pandemic • Double-digit percent growth in prescriber base YoY1 ✓ Grew overall PDP market and increased market share • Market growing (~4-5% YoY2) due to disease education/awa
Slide 14: NUPLAZID 2021 Growth Initiatives in PDP
NUPLAZID® 2021 Growth Initiatives in PDP ➢ Continue to grow base of new prescribers Grow ➢ Drive growth in overall PDP market size ➢ Increase market share with high new-to-treatment patient penetration ➢ Bridge the communication gap between physicians and patients/caregivers on PDP and treatment wit
Slide 15: Dementia-Related Psychosis: A Significant New Opportunity
Dementia-Related Psychosis: A Significant New Opportunity Dramatic Unmet Need HCP Awareness Caregiver Involvement No FDA-approved treatment Disease state education Disease awareness to include through websites and events multi-generational caregivers Unapproved atypical who often contribute to antip
Slide 16: Dementia-Related Psychosis: Ready for Launch
Dementia-Related Psychosis: Ready for Launch Brand ✓ NUPLAZID® brand established since 2016 launch Awareness Acadia ✓ Established support services (Acadia Connect) help Connect patients start and continue on NUPLAZID Market ✓ NUPLAZID has broad formulary access for PDP Access with a well recognized
Slide 17: R&D Update
R&D Update Serge Stankovic President
Slide 18: Innovative Development Pipeline
Innovative Development Pipeline Program Indication Phase 1 Phase 2 Phase 3 Registration Marketed NUPLAZID® Parkinson’s Disease (pimavanserin)1 Psychosis Dementia-Related Pimavanserin Psychosis Negative Symptoms of Pimavanserin Schizophrenia Trofinetide2 Rett Syndrome ACP-044 Acute & Chronic Pain ACP
Slide 19: Trofinetide for the Treatment of Rett Syndrome
Trofinetide for the Treatment of Rett Syndrome Trofinetide MOA: Phase 2 Study Results3 Novel synthetic analog of amino‐terminal tripeptide of IGF-1 with potential to reduce neuroinflammation and • 6-week, placebo-controlled dose ranging support synaptic function study in 82 young females (ages 5 – 1
Slide 20: Pimavanserin for the Treatment of the Negative Symptoms of Schizophrenia
Pimavanserin for the Treatment of the Negative Symptoms of Schizophrenia High Unmet Need1: ADVANCE-1 Results2 • No FDA-approved treatment for the negative • 26-week pivotal study in 403 patients with symptoms of schizophrenia predominant negative symptoms3 • >700K patients receiving treatment have •
Slide 21: ACP-044 for the Treatment of Acute and Chronic Pain
ACP-044 for the Treatment of Acute and Chronic Pain ACP-044 MOA: Phase 2 Program • A novel, first-in-class, orally administered, non-opioid analgesic • Interrupts multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a nitroxidative agent el
Slide 22: ACP-319 for the Treatment of Cognition and Schizophrenia
ACP-319 for the Treatment of Cognition and Schizophrenia ACP-319 MOA: ACP-319 Development Status • Positive Allosteric Modulator of the M1 receptor (M1 PAM) • Phase 1 program ongoing • Targets muscarinic (M1) receptors • Challenge with targeting the muscarinic system has been tolerability; associate
Slide 23: Clinical Development Timelines
Clinical Development Timelines EXPECTED COMPOUND INDICATION MILESTONE TIMING Dementia-Related Pimavanserin Psychosis PDUFA Date April 3, 2021 Acute Pain ACP-044 (Bunionectomy) Initiate Phase 2 Study 1Q21 Chronic Pain ACP-044 (Osteoarthritis) Initiate Phase 2 Study 2Q21 Phase 3 LAVENDER Study Trofine
Slide 24: CEO Closing Remarks
CEO Closing Remarks Steve Davis Chief Executive Officer
Slide 25: Building a Leading CNS Company
Building a Leading CNS Company Develop Next Wave of Combined Market Opportunity Breakthroughs: Deliver on the • Progressing Development DRP Opportunity: Candidates in 5 Indications • BD Strategy to Grow Pipeline Potential Future 10X Market Opportunity vs. PDP and Leverage CNS Expertise • Targeted Re
Slide 26: Q&A Session
C) ACADIA Q&A Session
ACADIA Pharmaceuticals — Q4 2020 Earnings Presentation on 6ix